SCHEDULE: Alyeska Group Discloses 9.9% Stake in Immunic

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has disclosed a 9.9% beneficial ownership stake in Immunic, Inc., primarily through warrants.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh collectively reported beneficial ownership of 9,485,936 shares of Immunic, Inc. Common Stock.
• This represents 9.9% of Immunic, Inc.'s outstanding Common Stock.
• The ownership is primarily through warrants to purchase 11,250,000 shares, subject to a 9.9% beneficial ownership limitation.
• As of June 30, 2025, the reporting persons may only exercise up to 9,485,936 shares under the warrant agreement due to the beneficial ownership limitation.
• The percentage calculation is based on 95,817,536 outstanding Common Stock of Immunic, Inc., as reported in the company's Form 10-Q filed on May 15, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a 9.9% beneficial ownership stake by a prominent investment group like Alyeska Investment Group, L.P. suggests a positive view on Immunic, Inc.'s prospects, even though the filing itself is a routine disclosure of ownership. The statement that the investment is for ordinary course of business and not for control is also a neutral to positive signal.

Positives

• A significant stake by an institutional investment group like Alyeska Investment Group may signal confidence in Immunic, Inc.'s long-term prospects.
• The investment is stated to be in the ordinary course of business, not for control, suggesting a passive investment interest.

Future Outlook

Not applicable, as this filing is a disclosure of past beneficial ownership, not a forward-looking statement from the issuer.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Immunic, Inc.

Industry Context

This filing indicates a significant institutional investment in Immunic, Inc., a biotechnology or pharmaceutical company. Such investments are common in the biotech sector, where institutional capital plays a crucial role in funding research and development and validating company prospects.

Comparison to Industry Standards

• A 9.9% stake is a substantial passive investment for an institutional fund, often indicating a long-term interest in the company's growth potential within the biotechnology sector.
• The use of warrants with a beneficial ownership cap is a common strategy for institutional investors to gain exposure while staying below certain reporting or control thresholds, aligning with typical investment practices in the industry.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor could potentially increase investor confidence and liquidity in Immunic, Inc.'s stock.

Key Dates

Recommendation

The filing indicates a significant beneficial ownership stake by Alyeska Investment Group, L.P., which can be interpreted as a vote of confidence from a sophisticated institutional investor. However, a Schedule 13G filing provides no information on the company's financial performance, strategic initiatives, or competitive landscape. Therefore, without additional fundamental analysis of Immunic, Inc., a "hold" recommendation is appropriate, acknowledging the institutional interest while awaiting more comprehensive data for a stronger stance.

Keywords

Immunic Inc, Alyeska Investment Group, Alyeska Fund GP, Anand Parekh, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, SEC filing